Results 221 to 230 of about 11,151,075 (302)

Exon 7 splicing of ERα predicts poor prognosis and increases phenotypic heterogeneity in luminal a subtype breast cancer

FEBS Open Bio, EarlyView.
ERα splice variant ERα∆7 lacks the C‐terminus, and its expression may change phenotypes of breast cancers. Our results showed that ERα∆7 is found in the luminal A subtype, and elevated ERα∆7 levels are linked to improved cell survival with lower proliferation and migration.
Long Wai Tsui, Taobo Hu, Thomson Christian Husein, Wai Hei Shek, Bingrong Chen, Depeng Wang, Shu Wang, Weichuan Yu, Xiaodan Fan, Mengping Long, Toyotaka Ishibashi   +10 more
wiley   +1 more source

Development and validation of search hedges for Transgender and Gender Diverse (TGD) populations in Ovid MEDLINE and Ovid APA PsycInfo. [PDF]

PLoS One
Gagen R, Marsalis S, Dinh C, Applejohn M, Shah R, Tong OX, Marshall Z, Everhart A.   +7 more
europepmc   +1 more source

Development of human monoclonal antibodies against TARM1 by yeast display

FEBS Open Bio, EarlyView.
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe, Mayumi Saeki, Masaaki Hashiguchi, Sayaka Ono, Kazuhisa Aoki, Hidetaka Tanno   +5 more
wiley   +1 more source

An open-access dataset of global experimental yields in organic, diversified and conventional agricultural systems. [PDF]

Data Brief
Sawadogo M, Ben-Ari T.
europepmc   +1 more source

Establishing an assay to evaluate d‐amino acid oxidase enzyme kinetics and inhibition using WST‐8 redox dye

FEBS Open Bio, EarlyView.
This study investigated a novel WST‐8‐based assay for evaluating d‐Amino acid oxidase (DAO) inhibitors. We confirmed its effectiveness using known inhibitors and found that uremic toxins possess relatively weak inhibitory activity compared to existing drugs.
Kahoko Miyake, Yuki Enoki, Yuka Nakazawa, Kazuaki Taguchi, Kazuaki Matsumoto   +4 more
wiley   +1 more source

Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EU. [PDF]

Front Med (Lausanne)
Van Isterdael C, Mugarza E, Fischer P, Debackere K, Vandenberghe P, Martin Lluesma S, Van Eldere J, Huys I.   +7 more
europepmc   +1 more source

RETRACTION: Mechanism of p27 Upregulation Induced by Downregulation of Cathepsin B and Upar in Glioma

Molecular Oncology, EarlyView.
RETRACTION: S. Gopinath, K. Alapati, R. R. Malla, C. S. Gondi, S. Mohanam, D. H. Dinh, and J. S. Rao, “Mechanism of p27 Upregulation Induced by Downregulation of Cathepsin B and Upar in Glioma,” Molecular Oncology 5, no. 5 (2011): 426–437, https://doi.org/10.1016/j.molonc.2011.07.004.
wiley   +1 more source

Screening and epitope characterization of Nidogen‐2‐specific nanobodies

FEBS Open Bio, EarlyView.
Camel immunization and phage display were employed to generate high‐affinity VHH nanobodies against Nidogen‐2. After library construction, biopanning, ELISA screening, sequencing, and recombinant expression, selected nanobodies were purified and characterized, leading to the preliminary exploration of a nanobody‐based sandwich ELISA for specific ...
Jianchuan Wen, Qianqian Cui, Zhongyun Lan, Yingjun Wang, Shuaiying Zhao, Wenxuan Feng, Yunfeng Liu, Qiting Huang, Dongna Zhang, Jianfeng Xu   +9 more
wiley   +1 more source

On the Importance of a Clear Definition of Time Horizon for Time-to-Event Dynamic Predictions: A Systematic Review and a Concrete Illustration in Kidney Transplantation. [PDF]

Clin Epidemiol
Chabeau L, Bonnemains V, Rinder P, Giral M, Desmée S, Dantan E.   +5 more
europepmc   +1 more source

Matrix metalloproteinase‐9 regulates cell adhesion and membrane protrusive activity of ovarian cancer cells

FEBS Open Bio, EarlyView.
Matrix metalloproteinase‐9 (MMP9) drives ovarian cancer progression. Using MMP9‐null cells (M9‐KO) created from ovarian cancer cells, we found MMP9 loss did not block Epidermal Growth Factor (EGF)‐driven E‐cadherin dissolution or EMT but delayed and reduced EGF‐driven membrane protrusions. Transient MMP9 re‐expression drove membrane protrusion.
Claire Strauel, Sam Bennett, Natalie Ehlinger, Nelson Cook, Katelyn Marvin, Caleb L. Lines, Sam Reyes, Brooke Kirby, Shawn M. Ellerbroek   +8 more
wiley   +1 more source